Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial

Nutrition and Metabolism

Volumn 5, Issue 1, 2008, Pages

  Lerman, Robert H ^a   Minich, Deanna M ^a   Darland, Gary ^a   Lamb, Joseph J ^a   Schiltz, Barbara ^a   Babish, John G ^a   Bland, Jeffrey S ^a   Tripp, Matthew L ^a  

^a MetaProteomics LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PHYTOSTEROL; PLANT MEDICINAL PRODUCT; PROANTHOCYANIDIN; RHO ISO ALPHA ACID; SOYBEAN PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AEROBIC EXERCISE; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC LOAD; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; OPEN STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ACACIA; HUMULUS;

EID: 57049090542     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-5-29     Document Type: Article

References (72)

1. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. M Fito M Guxens D Corella G Saez R Estruch R de la Torre F Frances C Cabezas C Lopez-Sabater Mdel J Marrugat A Garcia-Arellano F Aros V Ruiz-Gutierrez E Ros J Salas-Salvado M Fiol R Sola MI Covas, Arch Intern Med 2007 167 1195 1203 17563030
2. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. PN Mitrou V Kipnis AC Thiebaut J Reedy AF Subar E Wirfalt A Flood T Mouw AR Hollenbeck MF Leitzmann A Schatzkin, Arch Intern Med 2007 167 2461 2468 18071168
3. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. JH O'Keefe DS Bell, Am J Cardiol 2007 100 899 904 17719342
4. The metabolic syndrome. RH Eckel SM Grundy PZ Zimmet, Lancet 2005 365 1415 1428 15836891
5. Metabolic syndrome: a clinical and molecular perspective. DE Moller KD Kaufman, Annu Rev Med 2005 56 45 62 15660501
6. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. ES Ford, Diabetes Care 2005 28 2745 2749 16249550
7. Metabolic syndrome: from global epidemiology to individualized medicine. JA Batsis RE Nieto-Martinez F Lopez-Jimenez, Clin Pharmacol Ther 2007 82 509 524 17851562
8. Metabolic syndrome, or What you will: definitions and epidemiology. C Day, Diab Vasc Dis Res 2007 4 32 38 17469041
9. Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. CE Forsythe SD Phinney ML Fernandez EE Quann RJ Wood DM Bibus WJ Kraemer RD Feinman JS Volek, Lipids 2008 43 65 77 18046594
10. Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction. JS Volek RD Feinman, Nutr Metab (Lond) 2005 2 31 16288655
11. Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. JS Volek ML Fernandez RD Feinman SD Phinney, Prog Lipid Res 2008 47 307 318 18396172
12. Dietary fat, insulin sensitivity and the metabolic syndrome. G Riccardi R Giacco AA Rivellese, Clin Nutr 2004 23 447 456 15297079
13. Inflammation: the link between insulin resistance, obesity and diabetes. P Dandona A Aljada A Bandyopadhyay, Trends Immunol 2004 25 4 7 14698276
14. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. JD McGarry, Diabetes 2002 51 7 18 11756317
15. Lipotoxicity, overnutrition and energy metabolism in aging. M Slawik AJ Vidal-Puig, Ageing Res Rev 2006 5 144 164 16630750
16. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. G Boden X Chen J Rosner M Barton, Diabetes 1995 44 1239 1242 7556964
17. Fast elevation of the intramyocellular lipid content in the presence of circulating free fatty acids and hyperinsulinemia: a dynamic 1H-MRS study. K Brechtel DB Dahl J Machann OP Bachmann I Wenzel T Maier CD Claussen HU Haring S Jacob F Schick, Magn Reson Med 2001 45 179 183 11180422
18. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. DE Kelley MA Mintun SC Watkins JA Simoneau F Jadali A Fredrickson J Beattie R Theriault, J Clin Invest 1996 97 2705 2713 8675680
19. Mechanism of free fatty acid-induced insulin resistance in humans. M Roden TB Price G Perseghin KF Petersen DL Rothman GW Cline GI Shulman, J Clin Invest 1996 97 2859 2865 8675698
20. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. PA Permana C Menge PD Reaven, Biochem Biophys Res Commun 2006 341 507 514 16427608
21. Obesity is associated with macrophage accumulation in adipose tissue. SP Weisberg D McCann M Desai M Rosenbaum RL Leibel AW Ferrante Jr, J Clin Invest 2003 112 1796 1808 14679176
22. Effects of tumour necrosis factor-alpha and inhibition of protein kinase C on glucose uptake in L6 myoblasts. D Patiag S Gray I Idris R Donnelly, Clin Sci (Lond) 2000 99 303 307 10995595
23. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. P Plomgaard K Bouzakri R Krogh-Madsen B Mittendorfer JR Zierath BK Pedersen, Diabetes 2005 54 2939 2945 16186396
24. Effect of tumor necrosis factor-alpha on basal and insulin-stimulated glucose transport in cultured muscle and fat cells. S Ranganathan MB Davidson, Metabolism 1996 45 1089 1094 8781295
25. A reduced-glycemic load diet in the treatment of adolescent obesity. CB Ebbeling MM Leidig KB Sinclair JP Hangen DS Ludwig, Arch Pediatr Adolesc Med 2003 157 773 779 12912783
26. Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. CB Ebbeling MM Leidig KB Sinclair LG Seger-Shippee HA Feldman DS Ludwig, Am J Clin Nutr 2005 81 976 982 15883418
27. Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. KC Maki TM Rains VN Kaden KR Raneri MH Davidson, Am J Clin Nutr 2007 85 724 734 17344493
28. No difference in body weight decrease between a low-glycemic-index and a high-glycemic-index diet but reduced LDL cholesterol after 10-wk ad libitum intake of the low-glycemic-index diet. B Sloth I Krog-Mikkelsen A Flint I Tetens I Bjorck S Vinoy H Elmstahl A Astrup V Lang A Raben, Am J Clin Nutr 2004 80 337 347 15277154
29. Mediterranean diet and metabolic diseases. D Giugliano K Esposito, Curr Opin Lipidol 2008 19 63 68 18196989
30. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001 285 2486 2497 11368702
31. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. SM Grundy JI Cleeman SR Daniels KA Donato RH Eckel BA Franklin DJ Gordon RM Krauss PJ Savage SC Smith Jr JA Spertus F Costa, Circulation 2005 112 2735 2752 16157765
32. Are there specific treatments for the metabolic syndrome? D Giugliano A Ceriello K Esposito, Am J Clin Nutr 2008 87 8 11 18175731
33. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. JH O'Keefe NM Gheewala JO O'Keefe, J Am Coll Cardiol 2008 51 249 255 18206731
34. Imatinib attenuates diabetes-associated atherosclerosis. M Lassila TJ Allen Z Cao V Thallas KA Jandeleit-Dahm R Candido ME Cooper, Arterioscler Thromb Vasc Biol 2004 24 935 942 14988091
35. Molecular targets of curcumin. JK Lin, Adv Exp Med Biol 2007 595 227 243 17569214
36. Phytochemical genistein in the regulation of vascular function: new insights. H Si D Liu, Curr Med Chem 2007 14 2581 2589 17979711
37. Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. D Lukaczer DJ Liska RH Lerman G Darland B Schiltz M Tripp JS Bland, Nutrition 2006 22 104 113 16459222
38. Glycemic index of local foods and diets: the Mediterranean experience. G Riccardi G Clemente R Giacco, Nutr Rev 2003 61 S56 60 12828193
39. International table of glycemic index and glycemic load values: 2002. K Foster-Powell SH Holt JC Brand-Miller, Am J Clin Nutr 2002 76 5 56 12081815
40. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. JE Ware Jr CD Sherbourne, Med Care 1992 30 473 483 1593914
41. Development and validation of the food-craving inventory. MA White BL Whisenhunt DA Williamson FL Greenway RG Netemeyer, Obes Res 2002 10 107 114 11836456
42. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. SM Grundy R Pasternak P Greenland S Smith Jr V Fuster, J Am Coll Cardiol 1999 34 1348 1359 10520820
43. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. M Nauck GR Warnick N Rifai, Clin Chem 2002 48 236 254 11805004
44. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. KC Maki R Galant MH Davidson, Am J Cardiol 2005 96 59K 64K 16291016
45. Chromium and polyphenols from cinnamon improve insulin sensitivity. RA Anderson, Proc Nutr Soc 2008 67 48 53 18234131
46. The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. LK Heilbronn M Noakes PM Clifton, J Am Coll Nutr 2002 21 120 127 11999539
47. Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome. M Noakes PR Foster JB Keogh PM Clifton, J Nutr 2004 134 1894 1899 15284372
48. Fundamentals of beer and hop chemistry. D De Keukeleire, Química Nova 2000 23 108 112
49. Functional properties of hop polyphenols. D De Keukeleire L De Cooman H Rong A Heyerick J Kalita SR Milligan, Basic Life Sci 1999 66 739 760 10800471
50. Antimicrobial activity of Acacia nilotica (L.) Willd. ex Del. var. nilotica (Mimosaceae). OM Abd el Nabi EC Reisinger FF Reinthaler F Still U Eibel GJ Krejs, J Ethnopharmacol 1992 37 77 79 1453705
51. A study on the toxicology of Acacia nilotica. ZH Al-Mustafa AA Dafallah, Am J Chin Med 2000 28 123 129 10794124
52. A correlative study on antimutagenic and chemopreventive activity of Acacia auriculiformis A. Cunn. and Acacia nilotica (L.) Willd. Ex Del. K Kaur S Arora ME Hawthorne S Kaur S Kumar RG Mehta, Drug Chem Toxicol 2002 25 39 64 11850969
53. A Biology of Acacias. N TR, Melbourne, Oxford University Press 1984
54. Isohumulones modulate blood lipid status through the activation of PPAR alpha. M Shimura A Hasumi T Minato M Hosono Y Miura S Mizutani K Kondo S Oikawa A Yoshida, Biochim Biophys Acta 2005 1736 51 60 16099209
55. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. H Yajima E Ikeshima M Shiraki T Kanaya D Fujiwara H Odai N Tsuboyama-Kasaoka O Ezaki S Oikawa K Kondo, J Biol Chem 2004 279 33456 33462 15178687
56. Low-glycemic index diet in hyperlipidemia: use of traditional starchy foods. DJ Jenkins TM Wolever J Kalmusky S Guidici C Giordano R Patten GS Wong JN Bird M Hall G Buckley, Am J Clin Nutr 1987 46 66 71 3300252
57. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. K Esposito R Marfella M Ciotola C Di Palo F Giugliano G Giugliano M D'Armiento F D'Andrea D Giugliano, Jama 2004 292 1440 1446 15383514
58. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. TJ Orchard M Temprosa R Goldberg S Haffner R Ratner S Marcovina S Fowler, Ann Intern Med 2005 142 611 619 15838067
59. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. H Ghandehari S Kamal-Bahl ND Wong, Am Heart J 2008 156 112 119 18585505
60. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Y Cui RS Blumenthal JA Flaws MK Whiteman P Langenberg PS Bachorik TL Bush, Arch Intern Med 2001 161 1413 1419 11386890
61. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. W Lu HE Resnick KA Jablonski KL Jones AK Jain WJ Howard DC Robbins BV Howard, Diabetes Care 2003 26 16 23 12502653
62. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. I Shai EB Rimm SE Hankinson G Curhan JE Manson N Rifai MJ Stampfer J Ma, Circulation 2004 110 2824 2830 15492318
63. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone, Circulation 2004 110 227 239 15249516
64. Apolipoproteins as markers and managers of coronary risk. DC Chan GF Watts, Qjm 2006 99 277 287 16504986
65. Potential new risk factors for ischemic stroke: what is their potential? GJ Hankey, Stroke 2006 37 2181 2188 16809576
66. Impaired subcutaneous adipocyte lipogenesis is associated with systemic insulin resistance and increased apolipoprotein B/AI ratio in men and women. J Hoffstedt D Forster P Lofgren, J Intern Med 2007 262 131 139 17598821
67. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. E Ingelsson EJ Schaefer JH Contois JR McNamara L Sullivan MJ Keyes MJ Pencina C Schoonmaker PW Wilson RB D'Agostino RS Vasan, Jama 2007 298 776 785 17699011
68. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. A Onat G Can G Hergenc M Yazici A Karabulut S Albayrak, Int J Obes (Lond) 2007 31 1119 1125 17299378
69. Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease. M Rasouli AM Kiasari, Clin Biochem 2006 39 971 977 16963013
70. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. J Sierra-Johnson VK Somers FH Kuniyoshi CA Garza WL Isley AS Gami F Lopez-Jimenez, Am J Cardiol 2006 98 1369 1373 17134631
71. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. G Walldius I Jungner, J Intern Med 2006 259 493 519 16629855
72. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. S Yusuf S Hawken S Ounpuu T Dans A Avezum F Lanas M McQueen A Budaj P Pais J Varigos L Lisheng, Lancet 2004 364 937 952 15364185